{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:07:54Z","timestamp":1778018874509,"version":"3.51.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Multiple sclerosis is a neurodegenerative disease associated with demyelination and neuroinflammation in the central nervous system. There is an urgent need to develop remyelinating therapies to better treat multiple sclerosis and other demyelinating diseases. The kappa opioid receptor (KOR) has been identified as a potential target for the development of remyelinating therapies; however, prototypical KOR agonists, such as U50,488 have side effects, which limit clinical use. In the current study, we investigated a Salvinorin A analog, ethoxymethyl ether Salvinorin B (EOM SalB) in two preclinical models of demyelination in C57BL\/6J mice. We showed that in cellular assays EOM SalB was G-protein biased, an effect often correlated with fewer KOR-mediated side effects. In the experimental autoimmune encephalomyelitis model, we found that EOM SalB (0.1\u20130.3 mg\/kg) effectively decreased disease severity in a KOR-dependent manner and led to a greater number of animals in recovery compared to U50,488 treatment. Furthermore, EOM SalB treatment decreased immune cell infiltration and increased myelin levels in the central nervous system. In the cuprizone-induced demyelination model, we showed that EOM SalB (0.3 mg\/kg) administration led to an increase in the number of mature oligodendrocytes, the number of myelinated axons and the myelin thickness in the corpus callosum. Overall, EOM SalB was effective in two preclinical models of multiple sclerosis and demyelination, adding further evidence to show KOR agonists are a promising target for remyelinating therapies.<\/jats:p>","DOI":"10.3389\/fneur.2021.782190","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T08:37:31Z","timestamp":1639989451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Kelly F.","family":"Paton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Robichon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Denny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afnan","family":"Al Abadey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Prisinzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne C.","family":"La Flamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwyn M.","family":"Kivell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"B2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1474-4422(20)30140-X","article-title":"Remyelination in multiple sclerosis: from basic science to clinical translation","volume":"19","author":"Lubetzki","year":"2020","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11120","DOI":"10.1038\/ncomms11120","article-title":"Kappa opioid receptor activation alleviates experimental autoimmune encephalomyelitis and promotes oligodendrocyte-mediated remyelination","volume":"7","author":"Du","year":"2016","journal-title":"Nat Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"7925","DOI":"10.1523\/JNEUROSCI.1493-16.2016","article-title":"Identification of the kappa-opioid receptor as a therapeutic target for oligodendrocyte remyelination","author":"Mei","year":"2016","journal-title":"J Neurosci 36(30)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1021\/acs.jmedchem.8b01609","article-title":"Development of novel quinoxaline-based kappa-opioid receptor agonists for the treatment of neuroinflammation","volume":"62","author":"Tangherlini","year":"2019","journal-title":"J Med Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/BF00432213","article-title":"Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning","volume":"86","author":"Mucha","year":"1985","journal-title":"Psychopharmacology (Berl)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"12917","DOI":"10.1523\/JNEUROSCI.2444-15.2015","article-title":"Kappa opioid receptor-induced aversion requires p38 MAPK activation in VTA dopamine neurons","volume":"35","author":"Ehrich","year":"2015","journal-title":"J Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/aps.2014.145","article-title":"Novel kappa-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation","volume":"36","author":"Zhang","year":"2015","journal-title":"Acta Pharmacol Sin."},{"key":"B10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuropharm.2016.04.022","article-title":"kappa Opioid receptor activation in different brain regions differentially modulates anxiety-related behaviors in mice","volume":"110","author":"Wang","year":"2016","journal-title":"Neuropharmacology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1124\/jpet.120.000134","article-title":"Strategies for developing kappa opioid receptor agonists for the treatment of pain with fewer side effects","volume":"375","author":"Paton","year":"2020","journal-title":"J Pharmacol Exp Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/B978-0-12-420118-7.00012-3","article-title":"Salvinorin A analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse","volume":"69","author":"Kivell","year":"2013","journal-title":"Adv Pharmacol. (San Diego, Calif)."},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejphar.2013.10.050","article-title":"The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats","volume":"720","author":"Morani","year":"2013","journal-title":"Eur J Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fpsyt.2019.00157","article-title":"Cutting-edge search for safer opioid pain relief: retrospective review of salvinorin A and its analogs","volume":"10","author":"Zjawiony","year":"2019","journal-title":"Front Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3389\/fnins.2020.00765","article-title":"Evaluation of biased and balanced salvinorin a analogs in preclinical models of pain","volume":"14","author":"Paton","year":"2020","journal-title":"Front Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bmc.2007.10.067","article-title":"Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers","volume":"16","author":"Munro","year":"2008","journal-title":"Bioorg Med Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1039\/c1md00192b","article-title":"Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A","volume":"2","author":"Prevatt-Smith","year":"2011","journal-title":"Medchemcomm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s00213-017-4637-2","article-title":"The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and beta-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects","volume":"234","author":"Ewald","year":"2017","journal-title":"Psychopharmacology (Berl)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00213-010-1806-y","article-title":"Kinase cascades and ligand-directed signaling at the kappa opioid receptor","volume":"210","author":"Bruchas","year":"2010","journal-title":"Psychopharmacology (Berl)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell Signal."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1234","DOI":"10.1002\/cti2.1234","article-title":"Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease","volume":"10","author":"Denny","year":"2021","journal-title":"Clini Translat Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1750-3639.2001.tb00385.x","article-title":"The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system","volume":"11","author":"Matsushima","year":"2001","journal-title":"Brain Pathol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.neubiorev.2014.10.004","article-title":"Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis","volume":"47","author":"Praet","year":"2014","journal-title":"Neurosci Biobehav Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"10464","DOI":"10.1021\/jm501521d","article-title":"Synthesis and kappa-opioid receptor activity of furan-substituted salvinorin A analogues","volume":"57","author":"Riley","year":"2014","journal-title":"J Med Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"11027","DOI":"10.1021\/acs.jmedchem.6b01235","article-title":"Synthetic studies of neoclerodane diterpenes from salvia divinorum: identification of a potent and centrally acting mu opioid analgesic with reduced abuse liability","volume":"59","author":"Crowley","year":"2016","journal-title":"J Med Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.3390\/molecules23102602","article-title":"Kappa opioid receptor agonist mesyl Sal B attenuates behavioral sensitization to cocaine with fewer aversive side-effects than salvinorin A in rodents","volume":"23","author":"Kivell","year":"2018","journal-title":"Molecules."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0216113","DOI":"10.1371\/journal.pone.0216113","article-title":"Clozapine administration enhanced functional recovery after cuprizone demyelination","volume":"14","author":"Templeton","year":"2019","journal-title":"PLoS ONE."},{"key":"B29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbr.2007.02.009","article-title":"A comparison of the behavior of C57BL\/6 and C57BL\/10 mice","volume":"179","author":"Deacon","year":"2007","journal-title":"Behav Brain Res."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3791\/2609","article-title":"Measuring motor coordination in mice","author":"Deacon","year":"2013","journal-title":"J Vis Exp."},{"key":"B31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/13543784.2020.1757647","article-title":"New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis","volume":"29","author":"Villoslada","year":"2020","journal-title":"Expert Opin Investig Drugs."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/cen3.12354","article-title":"Clinical characteristics of autoimmune optic neuritis","volume":"8","author":"Kawachi","year":"2017","journal-title":"Clinical and Experimental Neuroimmunology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaneurol.2019.3283","article-title":"Using acute optic neuritis trials to assess neuroprotective and remyelinating therapies in multiple sclerosis","volume":"77","author":"Andorra","year":"2020","journal-title":"JAMA Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3233\/JAD-170036","article-title":"Remyelination: a potential therapeutic strategy for alzheimer's disease?","volume":"58","author":"Sun","year":"2017","journal-title":"J Alzheimers Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0163774","DOI":"10.1371\/journal.pone.0163774","article-title":"Alterations of myelin content in parkinson's disease: a cross-sectional neuroimaging study","volume":"11","author":"Dean","year":"2016","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-981-32-9636-7_17","article-title":"Therapeutic Strategies for Oligodendrocyte-Mediated Remyelination.","volume-title":"Myelin: Basic and Clinical Advances","author":"Ogata","year":"2019"},{"key":"B37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/bs.vh.2019.05.004","article-title":"Kappa opioid receptor and oligodendrocyte remyelination","volume":"111","author":"Wang","year":"2019","journal-title":"Vitam Horm."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3389\/fnins.2021.741503","article-title":"Multiple sclerosis and the endogenous opioid system","volume":"15","author":"Dworsky-Fried","year":"2021","journal-title":"Front Neurosci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"B40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo","volume":"352","author":"White","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ijnp\/pyy034","article-title":"Structurally related kappa opioid receptor agonists with substantial differential signaling bias: neuroendocrine and behavioral effects in C57BL6 mice","volume":"21","author":"Dunn","year":"2018","journal-title":"Int J Neuropsychopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fphar.2019.00407","article-title":"A review of the therapeutic potential of recently developed g protein-biased kappa agonists","volume":"10","author":"Mores","year":"2019","journal-title":"Front Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fphar.2020.00188","article-title":"Functional selectivity and antinociceptive effects of a novel KOPr agonist","volume":"11","author":"Bedini","year":"2020","journal-title":"Front Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1124\/mol.117.110890","article-title":"Biased agonism in drug discovery-is it too soon to choose a path?","volume":"93","author":"Michel","year":"2018","journal-title":"Mol Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.255661","article-title":"Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine","author":"Kaski","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br J Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jneuroim.2008.06.034","article-title":"MHC class II exacerbates demyelination in vivo independently of T cells","volume":"203","author":"Hiremath","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neubiorev.2019.08.008","article-title":"Behavioural phenotypes in the cuprizone model of central nervous system demyelination","volume":"107","author":"Sen","year":"2019","journal-title":"Neurosci Biobehav Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.toxlet.2007.01.010","article-title":"Behavioral deficits in the cuprizone-induced murine model of demyelination\/remyelination","volume":"169","author":"Franco-Pons","year":"2007","journal-title":"Toxicol Lett."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1759091414551955","DOI":"10.1177\/1759091414551955","article-title":"A new model of cuprizone-mediated demyelination\/remyelination","volume":"6","author":"Sachs","year":"2014","journal-title":"ASN Neuro."},{"key":"B51","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.expneurol.2016.06.033","article-title":"A mouse model for testing remyelinating therapies","volume":"283","author":"Bai","year":"2016","journal-title":"Exp Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.expneurol.2006.05.032","article-title":"Effects of commissural de- and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis","volume":"202","author":"Liebetanz","year":"2006","journal-title":"Exp Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e00013","DOI":"10.1042\/AN20090032","article-title":"Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination","volume":"1","author":"Hibbits","year":"2009","journal-title":"ASN Neuro."},{"key":"B54","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1073\/pnas.93.15.8051","article-title":"kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression","volume":"93","author":"Chao","year":"1996","journal-title":"Proc Nat Acad Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/(SICI)1098-1136(199802)22:2&lt;189::AID-GLIA10&gt;3.0.CO;2-U","article-title":"Endogenous opioid system in developing normal and jimpy oligodendrocytes: mu and kappa opioid receptors mediate differential mitogenic and growth responses","volume":"22","author":"Knapp","year":"1998","journal-title":"Glia."},{"key":"B56","doi-asserted-by":"publisher","first-page":"27662","DOI":"10.1074\/jbc.M502593200","article-title":"Mu and kappa opioid receptors activate ERK\/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes","volume":"280","author":"Belcheva","year":"2005","journal-title":"J Biol Chem."},{"key":"B57","doi-asserted-by":"publisher","first-page":"ENEURO","DOI":"10.1523\/ENEURO.0028-20.2020","article-title":"Characterization of a Knock-In Mouse Line Expressing a Fusion Protein of kappa Opioid Receptor Conjugated with tdTomato: 3-Dimensional Brain Imaging via CLARITY","volume":"7","author":"Chen","year":"2020","journal-title":"eNeuro."},{"key":"B58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fncel.2014.00073","article-title":"Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned","volume":"8","author":"Gudi","year":"2014","journal-title":"Front Cell Neurosci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.782190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T08:37:35Z","timestamp":1639989455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.782190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":58,"alternative-id":["10.3389\/fneur.2021.782190"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.782190","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"article-number":"782190"}}